iShares iBonds Dec 2028 Term Corporate ETF (ARCA: IBDT)

iShares iBonds Dec 2028 Term Corporate ETF (ARCA:IBDT), Trade Ideas

iShares iBonds Dec 2028 Term Corporate ETF

Jefferies analyst Andy Barish maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Hold and raises the price target from $120 to $136.

News

Price Target

Analyst Ratings

TXRH

Jefferies Maintains Hold on Texas Roadhouse, Raises Price Target to $136

Floridians are set to vote on a recreational marijuana constitutional amendment in November. Several key cannabis players are <a href="https://www.benzinga.com/markets/cannabis/24/04/38240431/biden-champions-cannabis-reform-and-pardon-as-election-pressure-mounts-marijuana-takes-center-st">preparing accordingly</a>.
What To Know: A panel of cannabis executives convened Tuesday at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> in Hollywood, Florida to discuss the economic pulse of the cannabis market.
&#8220;Florida has today a million medical card holders, 23 million people living in the state, 130 million, I think, visitors a year — it&#8217;s going to be huge,&#8221; says AYR Wellness CEO David Goubert said, referring to the vote.
At the beginning of April, the Florida Supreme Court&nbsp;proposed Amendment 3, which would legalize adult non-medical personal use of marijuana products and accessories. If approved, the proposal would take effect in May 2025.
Recreational adult use approval in Florida would be a major step forward for the industry given that Florida is the largest medical market, Goubert says. When approval occurs, sales usually go up between two and three times, he added.
Aaron Miles, CIO of Verano Holdings, is also very optimistic about the proposal in Florida. 
Verano&#8217;s strategy involves establishing a presence in states with limited licenses, taking market share and positioning itself ahead of adult-use legalization, he said. In Florida, the company already has 74 dispensaries and nearly 3,000 square feet of cultivation. 
Miles echoed a lot of what Goubert said about the sales boost that comes with recreational cannabis legalization and suggested that the proposal in Florida could have huge impacts on the company and the <a href="https://www.benzinga.com/cannabis">industry</a> as a whole. Florida has rules in place that make operations more profitable for cannabis companies as well, he added. 
&#8220;What we&#8217;re doing is making sure that we are going to be able to maximize every ounce of demand that would come out of the state,&#8221; Miles said.
Check This Out: <a href="https://www.benzinga.com/markets/cannabis/24/04/38272945/7-reasons-to-tune-into-the-benzinga-cannabis-capital-conference-in-person-or-virtually">7 Reasons To Tune Into The Benzinga Cannabis Capital Conference, In Person Or Virtually</a>
Jesse Channon, president of The Cannabist Company, said the entire cannabis industry is excited about potential regulatory changes in Florida this year. He suggested that the conversion to recreational use in Florida is inevitable and noted that his company is already preparing for additional states.
Other states with regulatory changes on the horizon include Virginia, Ohio, Pennsylvania, Delaware and West Virginia, he said.
&#8220;We deployed an enormous amount of Capex early on in building scaled facilities in pretty much all of the markets that I just mentioned, so as those markets mature and as they ultimately come to conversion for adult use, we&#8217;re really well positioned moreso than we have been in other markets prior,&#8221; Channon said. 
AdvisorShares CIO Dan Ahrens provided an investment perspective on the regulatory situation. Ahrens is the portfolio manager for the AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) and the AdvisorShares Pure Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>).
In general, he tries to manage the funds &#8220;gently&#8221; without a ton of movement, but when there is extra money in the fund, Ahrens looks to position in places with regulatory momentum, like the potential adult use legalization in Florida, he said. 
&#8220;All of the MSOs are very state-focused because we all know even if we get federal reform that we&#8217;re all expecting, there&#8217;s still going to be a state focus for adult use,&#8221; Ahrens said.
Want to watch our Cannabis Capital Conference live? For existing subscribers, you can get direct access <a href="https://www.benzinga.com/research/cannabis-capital-conference">through our research platform</a>. For new users, you can get <a href="https://www.benzinga.com/premium/ideas/sales-landing-2-2/">instant access here</a>!
Image: Pixabay

Cannabis

Events

MSOS

YOLO

EXCLUSIVE: Florida On Cusp Of Adult-Use Legalization Cannabis Sales Boom, CEO Tells Benzinga Conference — 'It's Going To Be Huge'

<a href="https://www.lvmh.com/news-documents/press-releases/lvmh-achieves-3-organic-revenue-growth-in-the-first-quarter/" title="https://www.lvmh.com/news-documents/press-releases/lvmh-achieves-3-organic-revenue-growth-in-the-first-quarter/">https://www.lvmh.com/news-documents/press-releases/lvmh-achieves-3-organic-revenue-growth-in-the-first-quarter/</a>

Earnings

LVMHF

LVMH Says Co Had Good Start To Year Despite Geopolitical And Economic Environment That Remains Uncertain; Says Europe And U.S. Achieved Growth On Constant Currency And Consolidation Scope Basis Over The Quarter; Says Japan Recorded Double-Digit Revenue Growth; The Rest Of Asia Reflected The Strong Growth In Spending By Chinese Customers In Europe And Japan

Adobe Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is developing an AI model capable of&nbsp;<a href="https://www.benzinga.com/news/24/04/38201081/whats-the-cost-of-training-generative-ai-with-videos-adobe-doles-out-money-for-acquiring-dataset" target="_blank" rel="noreferrer noopener">generating video content</a>, positioning itself in competition with other major players like OpenAI&#8217;s Sora and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&#8217;s Imagen 2 in the generative AI video technology field.&nbsp;
This new model is set to be integrated into Adobe&#8217;s flagship video editing software, Premiere Pro, later this year, expanding the Firefly family of generative AI products.&nbsp;
The model will facilitate the creation of footage from prompts or reference images and introduce three novel features in Premiere Pro: object addition, object removal, and generative extension, TechCrunch&nbsp;<a target="_blank" href="https://techcrunch.com/2024/04/15/adobes-working-on-generative-video-too/" rel="noreferrer noopener">reports</a>.&nbsp;
The features allow users to add or remove objects within video segments and extend clips by a few frames to enhance the final product, for example, by syncing with a soundtrack or adding emotional emphasis.
Addressing concerns about the potential misuse of AI tools to create deepfakes, Adobe plans to incorporate Content Credentials into Premiere to identify AI-generated content and the specific models used to make it.
 Reports suggest the company is paying creators on its Adobe Stock platform to contribute video clips to train the model.
Adobe also announced plans to integrate third-party tools from OpenAI, Runway, and Pika Labs into Premiere Pro, allowing users to generate and utilize video content directly within the software. 
By embracing these external AI technologies, Adobe aims to mitigate Wall Street&#8217;s concerns regarding the threat AI-generated content tools pose to its foundational business sectors, Reuters reports.
Prior reports indicated Adobe aggressively collecting videos to drive the development of its artificial intelligence text-to-video generator. The company tapped its community of photographers and artists, doling out $120 for footage showcasing a range of human activities and emotions.&nbsp;
Earlier at the Game Developers Conference, <a href="https://www.benzinga.com/news/24/03/37823241/adobes-latest-ai-features-transform-text-into-3d-textures-and-backgrounds-elevating-creative-workflo" target="_blank" rel="noreferrer noopener">the company launched</a> two innovative additions to its Substance 3D design software suite, empowering 3D artists to craft assets through mere text descriptions. 
The &#8220;Text to Texture&#8221; function within Substance 3D Sampler enables the creation of textures from text prompts. Furthermore, Adobe introduced the &#8220;Generative Background&#8221; tool in Substance 3D Stager, which generates background imagery for 3D settings from text descriptions. 
Adobe stock gained over 24% in the last 12 months. Investors can gain exposure to the stock via&nbsp;Invesco Next Gen Media And Gaming ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGME#NYSE">GGME</a>) and&nbsp;Invesco Nasdaq Internet ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNQI#NASDAQ">PNQI</a>).
Price Action:&nbsp;ADBE shares closed lower by 0.84% at $470.10 on Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Source &#8211; Shutterstock

Tech

Media

ADBE

GGME

GOOG

GOOGL

PNQI

Adobe's Latest AI Innovation Promises a New Era for Video Content Creation

Jefferies analyst Andy Barish maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Hold and raises the price target from $2350 to $2700.

Jefferies Maintains Hold on Chipotle Mexican Grill, Raises Price Target to $2700

TD Cowen analyst Bill Katz maintains KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) with a Buy and raises the price target from $144 to $154.

TD Cowen Maintains Buy on KKR, Raises Price Target to $154

LVMH Q1 2024 Revenue €20.7B

On Tuesday, Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>) delivered a rather mixed first quarter report.&nbsp;Adjusted earnings&nbsp;surpassed&nbsp;estimates&nbsp;as sales in its medical devices business surged, while revenue was almost in line with estimates. First quarter results came shortly after JNJ&rsquo;s&nbsp;expansion in the cardiovascular space with the&nbsp;$13.1 billion acquisition of heart device firm&nbsp;Shockwave Medical Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swav#NASDAQ">SWAV</a>).
<h3>First Quarter Highlights</h3>
For the period ended in March,&nbsp;the healthcare company&nbsp;posted a revenue of&nbsp;$21.38 billion, almost in line with LSEG&rsquo;s estimate of&nbsp;$21.4 billion. During the first three months of the year, revenue rose more than 2% YoY. JNJ reported a&nbsp;net income of $5.35 billion, or $2.20 per share, with adjusted income amounting to&nbsp;$2.71, surpassing LSEG&rsquo;s estimate of&nbsp;$2.64. It is quite a difference compared to last year&rsquo;s comparable quarter when JNJ posted a net loss due to costs related to its controversial&nbsp;talc baby powder liabilities&nbsp;that led to&nbsp;the spinoff of its consumer health unit. This quarter&rsquo;s success is owed to the thriving&nbsp;medical devices business&nbsp;that brought&nbsp;$7.82&nbsp;to the revenue table, rising more than&nbsp;4%&nbsp;on a YoY basis, with JNJ attributing the YoY rise to the acquisition of Abiomed.
On a less bright note, JNJ reported weak&nbsp;sales of vision care products and surgical devices.&nbsp;Vision products unit reported sales dropped&nbsp;3.3% to $1.26 billion, but JNJ is confident that there will be tremendous improvement going forward.
JNJ is also going strong against cancer.
Meanwhile, pharmaceutical sales brought in sales of&nbsp;$13.56 billion&nbsp;and grew about 1% YoY. However, the segment was brought down by its unpopular Covid vaccine as without it, pharmaceutical sales grew almost 7%. This growth is greatly owed to its cancer drugs, namely&nbsp;Darzalex,&nbsp;that treats&nbsp;multiple myeloma, and Erleada,&nbsp;a treatment forprostate cancer treatmet, along with other other oncology treatments such as&nbsp;Carvykti, a cell therapy&nbsp;that has been&nbsp;approved for a certain blood cancer. Analysts expect&nbsp;Dazalex&nbsp;to bring in sales of more than $11 billion&nbsp;this&nbsp;year, followed by Carvykti with&nbsp;$1.15 billion.
For two years now, JNJ has been making quite a few pushes into the cardiovascular space to strengthen the medical devices business upon the split from the consumer unit, as before Shockwave Medical, it already got&nbsp;Abiomed andLaminar.&nbsp;&nbsp;During the reported quarter,&nbsp;medical devices unit reported&nbsp;revenue of&nbsp;$7.82 billion&nbsp;boosted by strongdemand for Abiomed heart pumps, as well as&nbsp;devices used in wound closure surgeries, but analysts expected&nbsp;$7.88 billion.
But, the latest quarter shows it is also strengthening its position in the cancer battle,&nbsp;joining the efforts of Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) and Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) who are also turning to oncology to fight falling sales of Covid products. Both Pfizer and Moderna are betting big on cancer drugs to turn business around. Pfizer acquired the cancer drug maker specialist&nbsp;Seagen, thanks to which it expects&nbsp;to have&nbsp;at least eight blockbuster medicines by&nbsp;the end of the decade.&nbsp;Pfizer is going against&nbsp;four main types of cancer: breast cancer; genitourinary cancer,&nbsp;thoracic cancer,&nbsp;and&nbsp;hematology-oncology&nbsp;cancer. Meanwhile, Moderna developed&nbsp;an&nbsp;individualized cancer vaccine with Merck. Last year, Moderna reported mid-stage results of the combined treatment that were promising against melanoma.&nbsp;Last week, Moderna reported the treatment showed a&nbsp;positive response in an early-stage trial&nbsp;also in patients&nbsp;suffering from a type of&nbsp;head and neck cancer.&nbsp;Unsurprisingly, Moderna shares rose to a three month high upon the news last Tuesday.
<h3>A Narrowed Full Year Guidance</h3>
JNJ guided for full year sales between&nbsp;$88 billion to $88.4 billion, narrowing down its prior range from&nbsp;$87.8 billion to $88.6 billion.&nbsp;As for adjusted earnings, JNJ provided a range between&nbsp;$10.57&nbsp;and&nbsp;$10.72 per share, also narrowing down its prior forecast that was between&nbsp;$10.55&nbsp;and&nbsp;$10.75. However, considering that the acquisition of Shockwave Medical is&nbsp;expected to&nbsp;close in the middle of the year,&nbsp;it will undoubtedly alter JNJ&rsquo;s full year guidance.
JNJ is often viewed as a reflection of the healthcare industry trends. With its latest results,&nbsp;the pharmaceutical giantshowed the sector is determined in finally winning the battle against cancer.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Health Care

General

MRNA

SWAV

Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff

Jefferies analyst Andy Barish maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Hold and lowers the price target from $100 to $94.

SBUX

Jefferies Maintains Hold on Starbucks, Lowers Price Target to $94

Calidi Biotherapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#NASDAQ">CLDI</a>) shares are trading lower by 59% to $0.25 during Tuesday&#8217;s session after the company announced the pricing of a <a href="https://www.benzinga.com/pressreleases/24/04/b38268667/calidi-biotherapeutics-inc-announces-pricing-of-6-1-million-public-offering">$6.1 million public offering</a>.
The offering includes various types of warrants with different exercise prices and expiration dates. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials. 
The offering is expected to close around April 18, pending customary closing conditions, with Ladenburg Thalmann &amp; Co. Inc. serving as the sole placement agent.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38265826/high-interest-rates-could-cause-more-things-to-break-in-us-economy-by-2025-warns-st">High-Interest Rates Could Cause &#8216;More Things To Break&#8217; In US Economy By 2025, Warns Strategist</a>
<h2 class="wp-block-heading">How To Buy CLDI Stock</h2>
By now you're likely curious about how to participate in the market for Calidi Biotherapeutics &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of Calidi Biotherapeutics, which is trading at $0.28 as of publishing time, $100 would buy you 357.14 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CLDI has a 52-week high of $5.00 and a 52-week low of $0.25.

CLDI

Why Calidi Biotherapeutics (CLDI) Shares Are Down Over 50%

Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares are trading higher Tuesday after the company announced it has signed an exclusive 5-year in-license<a href="https://www.benzinga.com/pressreleases/24/04/ac38268700/jaguar-health-licenses-fda-approved-oral-mucositis-product-for-u-s-market-initiating-commercial-f"> agreement with Venture Life Group PLC.</a>
The Details:
The license agreement is for the U.S. market for Venture Life's FDA-approved prescription product, Gelclair. Gelclair is used for the treatment of oral mucositis, also called &#8220;chemo mouth.&#8221;&nbsp;
&#8220;We are very happy to have executed the in-license agreement for Gelclair &#8211; and thus to have initiated Jaguar&#8217;s commercial footprint in our core focus area of cancer supportive care,&#8221; said Lisa Conte, Jaguar&#8217;s president and CEO.
Jaguar Health shares are moving on heavy trading volume following the announcement with more than 240 million shares already traded in the session. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, the stock&#8217;s 100-day average volume is 46.306 million shares.
Related News: <a href="https://www.benzinga.com/news/24/04/38255034/whats-going-on-with-rivian-automotive-stock">What&#8217;s Going On With Rivian Automotive Stock?</a>
<h2 class="wp-block-heading">Should I Sell My JAGX Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Jaguar Health have decreased by 68.97% in the past year. An investor who bought shares of Jaguar Health at the beginning of the year would make a profit of $0.04 per share if they sold it today. The stock has risen 172.33% over the past month, meaning an investor who bought shares on Mar. 1 would see a capital gain of $0.05.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Jaguar Health stock currently has an RSI of 70.7, indicating overbought conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
JAGX Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Jaguar Health shares are up 49.5% at 18 cents at the time of publication Tuesday.
Image from Shutterstock

Penny Stocks

Movers

JAGX

Why Jaguar Health Stock Is Up Today

TD Cowen analyst Bill Kirk maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Buy and raises the price target from $87 to $92.

SCHW

TD Cowen Maintains Buy on Charles Schwab, Raises Price Target to $92

Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares are trading higher Tuesday after the company announced the completion of its analysis <a href="https://www.benzinga.com/pressreleases/24/04/g38268575/palisade-bio-successfully-demonstrates-bioactivation-of-pali-2108-in-ex-vivo-study-of-normal-healt">evaluating ex-vivo bioactivation of PALI-2108.</a>
The Details:
Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis (UC). The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.
&#8220;The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC,&#8221; said Dr. Mitch Jones, CMO at Palisade Bio.&nbsp;
&#8220;The successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor form at consistently high conversion rates over a 24-hour period in stool samples highlights its promise as an innovative therapeutic approach for managing UCl," Jones added.&nbsp;
Palisade Bio shares are trending on social media and moving on heavy trading volume Tuesday. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 13.2 million shares have already been traded in the session, compared to the stock&#8217;s 100-day average of less than 192,000 shares.
Related News: <a href="https://www.benzinga.com/news/24/04/38255034/whats-going-on-with-rivian-automotive-stock">What&#8217;s Going On With Rivian Automotive Stock?</a>
<h2 class="wp-block-heading">How To Buy PALI Stock:</h2>
By now you're likely curious about how to participate in the market for Palisade Bio &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
PALI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Palisade Bio shares are up 60.8% at $6.69 at the time of publication Tuesday.
Image: Myriams-Fotos from Pixabay

PALI

Why Palisade Bio Stock Is Soaring Today

Tuesday,&nbsp;IGC Pharma Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) released interim data from its Phase 2 clinical trial of IGC-AD1 for agitation in dementia&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38266079/igc-ad1s-interim-phase-2-data-show-a-reduction-in-alzheimers-agitation-at-week-two" rel="noreferrer noopener">associated with Alzheimer&#8217;s</a>.
The data demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer&#8217;s at week two&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37853677/alzheimers-focused-small-cap-firm-igc-pharma-releases-data-candidate-reduces-agitation-compared-t" rel="noreferrer noopener">compared to placebo</a>.
IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug contains THC as one of two active pharmaceutical agents.&nbsp;
&#8220;We are excited to share that the interim results on the secondary outcome show that IGC-AD1 can provide fast relief with few side effects in reducing agitation in Alzheimer&#8217;s dementia compared to placebo,&#8221; said Ram Mukunda, CEO of IGC Pharma.
&#8220;Approximately 6.5 million individuals in the U.S. live with Alzheimer&#8217;s and a majority experience a medical syndrome called agitation in Alzheimer&#8217;s dementia&#8230;The interim data indicate early signs of potential clinical benefit with IGC-AD1 with infrequent treatment-limiting side effects,&#8221; added Mukunda.
The secondary outcome, as measured by the change in agitation versus placebo using a standard measurement scale, the Cohen Mansfield Agitation Inventory (CMAI) at baseline and week 2, exhibited an Effect Size (ES) of 0.79 (p=0.071), indicating a large magnitude of difference between the active and placebo groups.&nbsp;
For context, a study published in 2003 concluded that an effect size over 0.5 corresponds to a noticeable change to a careful observer, highlighting the notable impact of IGC-AD1.&nbsp;
In May 2023, the FDA approved&nbsp;Otsuka Holding Co Ltd&#8217;s&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTSKY#OTC">OTSKY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OTSKF#OTC">OTSKF</a>) Rexulti (brexpiprazole), an atypical antipsychotic, with a boxed warning. This approval followed a significantly larger 12-week Phase 3 trial, which showed a Cohen&#8217;s d effect size of 0.35, whereas IGC-AD1 showed an effect size of 0.79 in two weeks.
The ongoing 146-patient clinical trial is a multicenter, double-blind, randomized, placebo-controlled study designed to assess the safety and efficacy of IGC-AD1 in treating agitation in dementia due to Alzheimer&#8217;s.&nbsp;
Over 1,000 oral doses have been administered to date, with no dose-limiting adverse events observed.
Price Action: IGC shares are up 19.50% at $0.52 on the last check Tuesday.
Image: Wally Crawfish from Pixabay

Biotech

OTSKF

OTSKY

IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation

Jefferies analyst Andy Barish maintains Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) with a Hold and raises the price target from $455 to $480.

Jefferies Maintains Hold on Domino's Pizza, Raises Price Target to $480

High-rolling investors have positioned themselves bearish on Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SBUX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Starbucks. This is not a typical pattern.
The sentiment among these major traders is split, with 33% bullish and 66% bearish. Among all the options we identified, there was one put, amounting to $66,105, and 8 calls, totaling $342,645.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $75.0 and $95.0 for Starbucks, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Starbucks options trades today is 4536.25 with a total volume of 2,412.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Starbucks's big money trades within a strike price range of $75.0 to $95.0 over the last 30 days.
<h3>Starbucks Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713282387_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$3.6</td>
<td>$3.5</td>
<td>$3.6</td>
<td>$85.00</td>
<td>$72.0K</td>
<td>2.1K</td>
<td>189</td>
</tr>
<tr>
<td>SBUX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$5.65</td>
<td>$5.55</td>
<td>$5.65</td>
<td>$80.00</td>
<td>$66.1K</td>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$21.35</td>
<td>$18.95</td>
<td>$20.4</td>
<td>$75.00</td>
<td>$61.2K</td>
<td>6</td>
<td>30</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$1.99</td>
<td>$1.95</td>
<td>$1.97</td>
<td>$90.00</td>
<td>$59.1K</td>
<td>17.5K</td>
<td>503</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$2.15</td>
<td>$2.12</td>
<td>$2.12</td>
<td>$90.00</td>
<td>$42.4K</td>
<td>17.5K</td>
<td>1.2K</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 38,000 stores across more than 80 countries as of the end of fiscal 2023. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
In light of the recent options history for Starbucks, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Starbucks</h3>
<ul>
<li>With a volume of 2,260,705, the price of SBUX is down -0.02% at $85.16. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 14 days.</li>
</ul>
<h3>Professional Analyst Ratings for Starbucks</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $104.0.
<ul>
<li>An analyst from JP Morgan persists with their Overweight rating on Starbucks, maintaining a target price of $100. </li>
<li>In a cautious move, an analyst from TD Cowen downgraded its rating to Hold, setting a price target of $100. </li>
<li>An analyst from Morgan Stanley persists with their Overweight rating on Starbucks, maintaining a target price of $115. </li>
<li>Maintaining their stance, an analyst from TD Cowen continues to hold a Hold rating for Starbucks, targeting a price of $100. </li>
<li>An analyst from Wells Fargo persists with their Overweight rating on Starbucks, maintaining a target price of $105. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Starbucks options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Spotlight on Starbucks: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on American Airlines Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with AAL, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for American Airlines Gr.
This isn't normal.
The overall sentiment of these big-money traders is split between 87% bullish and 12%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $706,283, and there was 1 call, for a total amount of $27,500.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $25.0 for American Airlines Gr over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for American Airlines Gr's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of American Airlines Gr's whale activity within a strike price range from $10.0 to $25.0 in the last 30 days. 
<h3>American Airlines Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713282382_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.0</td>
<td>$12.1</td>
<td>$12.1</td>
<td>$25.00</td>
<td>$363.0K</td>
<td>0</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.13</td>
<td>$0.1</td>
<td>$0.12</td>
<td>$10.00</td>
<td>$120.0K</td>
<td>137.2K</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$16.00</td>
<td>$55.2K</td>
<td>9</td>
<td style="text-align: right;">135</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$0.53</td>
<td>$0.52</td>
<td>$0.52</td>
<td>$11.00</td>
<td>$45.6K</td>
<td>12.4K</td>
<td style="text-align: right;">184</td>
</tr>
<tr>
<td>AAL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.4</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$16.00</td>
<td>$45.2K</td>
<td>9</td>
<td style="text-align: right;">135</td>
</tr>
</tbody>
</table>

<h3>About American Airlines Gr</h3>
American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major U.S. hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of U.S. airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
After a thorough review of the options trading surrounding American Airlines Gr, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is American Airlines Gr Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 9,772,929, the AAL's price is up by 0.5%, now at $13.01. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 13 days.</li>
</ul>
<h3>Professional Analyst Ratings for American Airlines Gr</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $19.0.
<ul>
<li>An analyst from UBS has revised its rating downward to Buy, adjusting the price target to $19. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for American Airlines Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

American Airlines Gr's Options Frenzy: What You Need to Know

ADDYY

Adidas Q1 2024 Revenue EUR$5.46B, Gross Margin 51.2%

Whales with a lot of money to spend have taken a noticeably bearish stance on Celsius Holdings.
Looking at options history for Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 63% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $349,014 and 5, calls, for a total amount of $350,191.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $100.0 for Celsius Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Celsius Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Celsius Holdings's whale activity within a strike price range from $60.0 to $100.0 in the last 30 days. 
<h3>Celsius Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713282377_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$6.5</td>
<td>$5.7</td>
<td>$6.5</td>
<td>$80.00</td>
<td>$130.0K</td>
<td>3.9K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$1.69</td>
<td>$1.5</td>
<td>$1.52</td>
<td>$77.00</td>
<td>$127.1K</td>
<td>45</td>
<td style="text-align: right;">836</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$2.33</td>
<td>$2.25</td>
<td>$2.33</td>
<td>$100.00</td>
<td>$116.5K</td>
<td>1.8K</td>
<td style="text-align: right;">24</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$7.35</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$80.00</td>
<td>$65.0K</td>
<td>3.9K</td>
<td style="text-align: right;">300</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$6.2</td>
<td>$80.00</td>
<td>$58.9K</td>
<td>3.9K</td>
<td style="text-align: right;">923</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages (including those that are naturally caffeinated with stevia), Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius focuses its time on branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
Following our analysis of the options activities associated with Celsius Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Celsius Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,572,954, the price of CELH is down by -0.64%, reaching $73.02.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 21 days from now.</li>
</ul>
<h3>Expert Opinions on Celsius Holdings</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $75.0.
<ul>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Celsius Holdings with a target price of $75. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Celsius Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

iShares iBonds Dec 2028 Term Corporate ETF (ARCA:IBDT), Trade Ideas